1	TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 -
2	The Vall d'Hebron COVID-19 prospective cohort study.
3	TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 -
4	The Vall d'Hebron COVID-19 prospective cohort study.
5	
6	Adrián Sánchez-Montalvá, MD, PhD, <sup>1,8,9</sup> Júlia Sellarés-Nadal, MD, <sup>1</sup> Juan Espinosa-
7	Pereiro, MD, <sup>1,8</sup> Nuria Fernández-Hidalgo, MD, PhD, <sup>1,10</sup> Santiago Pérez-Hoyos, PhD, <sup>2</sup>
8	Fernando Salvador, MD, PhD, <sup>1,8,9</sup> Xavier Durà, MD, <sup>1</sup> Marta Miarons, Pharm D,
9	PhD, <sup>3</sup> Andrés Antón, PhD, <sup>4,10</sup> Simeón Eremiev-Eremiev, MD, <sup>1</sup> Abiu Sempere-
10	González, MD, <sup>1</sup> Arnau Monforte-Pallarés, MD, <sup>1</sup> Pau Bosch-Nicolau, MD, <sup>1</sup> Salvador
11	Augustin, MD, PhD, <sup>5</sup> Júlia Sampol, MD, <sup>6</sup> Alfredo Guillén-del-Castillo, MD, PhD, <sup>7</sup>
12	Benito Almirante MD, PhD. <sup>1,10</sup>
13	<sup>1</sup> Infectious Diseases Department, Vall d'Hebron University Hospital, Universitat
14	Autònoma de Barcelona, Barcelona, Spain;
15	<sup>2</sup> Statistic Unit, Vall d'Hebron Institute of Research, Barcelona, Spain;
16	<sup>3</sup> Pharmacy Department, Vall d'Hebron University Hospital, Universitat Autònoma de
17	Barcelona, Barcelona, Spain;
18	<sup>4</sup> Microbiology Department, Vall d'Hebron University Hospital, Universitat Autònoma de
19	Barcelona, Barcelona, Spain;
20	<sup>5</sup> Hepatology Department, Vall d'Hebron University Hospital, Universitat Autònoma de
21	Barcelona, Barcelona, Spain;
22	<sup>6</sup> Pneumology Department, Vall d'Hebron University Hospital, Universitat Autònoma de
23	Barcelona, Barcelona, Spain;

- <sup>24</sup> <sup>7</sup>Internal Medicine Department, Vall d'Hebron University Hospital, Universitat Autònoma
- 25 de Barcelona, Barcelona, Spain;
- <sup>8</sup>International Health Program of the Catalan Institut of Health (PROSICS), Barcelona,
- 27 Spain;
- <sup>9</sup>Tropical Medicine Spanish Research Network (RICET), Madrid, Spain;
- <sup>10</sup>Infectous Diseases Spanish Research Network (REIPI), Madrid, Spain;
- 30

# 31 Address correspondence to:

- 32 Adrián Sánchez-Montalvá, MD, PhD (corresponding author)
- 33 Address: Passeig Vall d'Hebron, 119-129. Hospital Universitario Vall d'Hebron. Edificio
- 34 General. Enfermedades Infecciosas. 6<sup>a</sup> planta. CP 08035. Barcelona. Spain.
- e-mail: adsanche@vhebron.net . Telephone number: +34 93 274 6090 Fax number: +34 93

36 489 40 91.

- 37 **Running title:** Tocilizumab in COVID19
- 38 Word count (abstract): 249
- **Word count:** 3742
- 40 **Tables:** 7
- 41 **Figures:** 4
- 42 **Sources of funding:** none.
- 43 Summary of the article's main point: In patient with COVID-19 and lung injury, time
- 44 from lung injury onset to tocilizumab administration may be critical to patient recovery.
- 45 Early administration of host-directed therapies may improve patient outcome.

# 46 ABSTRACT

47	<b>Background:</b> Modulation of the immune system to prevent lung injury is being widely
48	used against the new coronavirus disease (COVID-19) despite the scarcity of evidence.
49	Methods: We report the preliminary results from the Vall d'Hebron prospective cohort
50	study at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive
51	patients who had a confirmed infection with the severe acute respiratory syndrome
52	coronavirus-2 (SARS-CoV-2) and who were treated with tocilizumab until March 25 <sup>th</sup> . The
53	primary endpoint was mortality at 7 days after tocilizumab administration. Secondary
54	endpoints were admission to the intensive care unit, development of ARDS and respiratory
55	insufficiency among others.
56	Results: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean
57	$(\pm$ SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and
58	the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory
59	failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median
60	time from symptom onset to ARDS development was 8 (5-11) days. The median time from
61	symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was
62	26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for
63	mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS.
64	Conclusion: Time from lung injury onset to tocilizumab administration may be critical to
65	patient recovery. Our preliminary data could inform bedside decisions until more data from
66	clinical trials becomes available.
67	

68

## 69 **INTRODUCTION:**

Coronavirus disease 2019 (COVID-19) is a novel illness caused by severe acute respiratory 70 syndrome coronavirus-2 (SARS-CoV-2). It was first reported in December 2019 in Hubei 71 province, China.<sup>1</sup> Since then, SARS-CoV-2 has rapidly spread worldwide. 72 According to the World Health Organization (WHO), as of July 8<sup>th</sup>, 2020, there have been 73 11.669.259 laboratory-confirmed cases and 539.906 deaths.<sup>2</sup> The crude case fatality rate. 74 estimated to be between 2.3% and 3.3%, is highly dependent on age and underlying 75 conditions.<sup>3,4</sup> Death is mainly due to respiratory failure caused by an acute respiratory 76 77 distress syndrome (ARDS). As the pathophisiology behind lung injury is progressively elucidated, several therapies have been proposed on the basis of pre-clinical studies and the 78 previous experience with the severe acute respiratory syndrome coronavirus (SARS-CoV) 79 and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).<sup>5,6</sup> Many of them 80 81 are being used off-label in a desperate attempt to improve patient outcomes, including antiviral therapies, coagulation-modifying drugs and immune-modulating therapies.<sup>7–11</sup> 82 83 In COVID-19, an excessive immune response inducing disproportionate release of 84 cytokines and hyperinflammation has been proposed as a cause for the lung damage, mimicking a secondary haemophagocytic lymphohistiocytosis.<sup>12</sup> Host-directed therapies 85 have immune-modulating properties with higher precision than steroids and other immune-86 modulating therapies.<sup>13</sup> Tocilizumab is a humanized monoclonal antibody that inhibits 87 interleukin-6 (IL-6) receptor with a well-known safety profile and is approved for the 88 treatment of rheumatoid arthritis and, since 2017, the treatment of chimeric antigen receptor 89 (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).<sup>14,15</sup> It 90 has been used with promising results in small retrospective cohort studies of SARS-CoV-2 91 infected patients in China.<sup>9,16</sup> The efficacy of other host-directed therapies targeting 92

- 93 hyperinflammation is being assessed under randomized clinical trial conditions for severe
- 94 SARS-CoV-2 infected patients.<sup>17,18</sup>
- 95 However, a proper characterization of the subset of patients who will benefit most from
- 96 host-directed therapy and defining the precise timing for host-directed therapies
- administration has not yet been performed and is critical to allocate limited drug stocks and
- reduce COVID-19 associated mortality. We aim to describe a prospective cohort of SARS-
- 99 CoV-2 infected patients treated with tocilizumab and define risk factors associated with
- 100 poor outcome.

## 101 **METHODS**

### 102 Study setting and population

- 103 The Vall d'Hebron COVID-19 Prospective Cohort Study includes all consecutive adult
- 104 patients (≥ 18 years old) treated for COVID-19 at Vall d'Hebron University Hospital, a
- 105 1100-bed public tertiary care hospital in Barcelona, Spain. For this study we selected the
- subgroup of patients with laboratory-confirmed COVID-19 and radiologically confirmed
- 107 pneumonia who received at least one dose of tocilizumab. Identification and inclusion of
- 108 patients receiving tocilizumab was performed from the Pharmacy Department registry.

## 109 Standard of care and tocilizumab administration criteria

- 110 At admission, all patients were initially evaluated with chest radiography and blood tests
- 111 including complete cell count, coagulation studies, biochemistry and inflammatory
- 112 parameters. Treatment with lopinavir/ritonavir, azithromycin and hydroxychloroquine was
- 113 initiated according to Vall d'Hebron University Hospital protocol. Tocilizumab was
- 114 considered as additional treatment in patients with the following criteria: 1) respiratory
- failure defined as a ratio of arterial oxygen tension to fraction of inspired oxygen
- 116 (PaO2/FiO2 ratio) of <300, a ratio of arterial oxygen saturation measured by pulse
- 117 oximetry to fraction of inspired oxygen (SpO2/FiO2 ratio) of <315 or pO2 <60mmHg or
- 118 oxygen saturation measured by pulse oximetry less than 90% when breathing room air or
- 119 rapidly progressive clinical worsening according to treating physician and 2) interleukin-6
- 120 (IL-6) levels >40pg/mL (reference 0-4.3pg/mL) or a D-dimer levels > 1500 ng/mL
- 121 (reference 0-243 pg/mL). Two dosing regimens based on weight were considered for
- tocilizumab. Patients over 75kg received 600mg, otherwise 400mg was the preferred dose.
- 123 A second dose was considered in patients with a poor early response. Patients with liver
- 124 enzymes (aspartate aminotransferase and alanine aminotransferase) 5 times over the upper

125 limit of normality or concomitant severe bacterial infection were not eligible for

- 126 tocilizumab treatment.
- 127 Data sources
- 128 Data were collected retrospectively from the medical charts of tpatients from the 13<sup>th</sup> of

129 March, 2020 to the  $18^{th}$  of March, 2020, when the protocol was submitted to the

130 institutional review board, and prospectively thereafter. Inclusion and follow-up are still

131 ongoing. The cut-off data for inclusion in this sub-study was the 25<sup>th</sup> of March, 2020. All

132 patients included were followed for at least 7 days. The institutional review board provided

133 ethical clearance (local review board code number: PR(AG)183/2020). Patients were asked

134 for an oral consent. The institutional review board granted an informed consent waiver if

135 patients were unable to give oral consent. Written consent was waived because of the crisis

136 context and concerns about safety when introducing a physical support for the consent in

137 the isolation areas.

138 A Laboratory-confirmed case was defined as a patient with a real-time reverse-

139 transcriptase-polymerase-chain-reaction (RT-PCR) SARS-CoV-2 positive result in any

140 respiratory sample (nasopharyngeal swab, sputum, bronchoalveolar lavage or aspirate,

141 tracheal aspirate).

We collected sociodemographic characteristics, past medical history, Charlson comorbidity score, concomitant medication, current therapy, adverse drug events, blood test results, imaging studies, microbiological tests other than SARS-CoV-2 RT-PCR on respiratory samples when available, and supportive measures needed. Vital signs, symptoms and physical examination were evaluated on admission, at 48h and weekly during hospital admission. Laboratory, microbiology and imaging studies were performed on admission and thereafter according to the clinical care needs of each patient. Laboratory assessments

149	consisted of a complete blood count, coagulation testing including D-dimer measurement,
150	liver and renal tests, electrolyte profile, and inflammatory profile including C-reactive
151	protein, fibrinogen, ferritin and IL-6. All radiographs were reviewed by the investigators
152	and computed tomography (CT) scans were recorded according to the radiology department
153	reports. The COVID-19 severity was measured with the CURB-65 scale for community
154	acquired pneumonia and other scales. <sup>19,20</sup> Data was recorded in the Research Electronic
155	Data Capture software (REDCap, Vanderbilt University).
156	Laboratory confirmation
157	From the onset of the outbreak until 15 <sup>th</sup> of March the microbiological diagnosis was based
158	on a homebrew RT-PCR assay targeting two viral targets (N1 and N2) in the viral
159	nucleocapsid (N) gene and one in the envelope (E) gene of SARS-CoV-2, as well as the
160	human RNase P (RP) gene as an internal control of the whole process, according to the

161 CDC and ECDC Real-Time RT-PCR Diagnostic Panels with minor modifications.<sup>21</sup> Since

162 March 15<sup>th</sup>, commercial Allplex<sup>TM</sup> 2019-nCoV multiplex RT-PCR (Seegene, South Korea)

163 were used for the detection of three viral targets (E; N; and, RNA-dependent RNA

164 polymerase, RdRp) and an internal control. First SARS-CoV-2 laboratory-confirmations

165 were confirmed by RdRp sequencing.<sup>22,23</sup> Total nucleic acids (DNA/RNA) were extracted

166 from respiratory specimens using NucliSENS easyMAG (BioMerieux, France)

and STARMag Universal Cartridge Kit (Seegene, South Korea) according to the

168 manufacturer's instructions. All microbiological procedures were carried out in the

169 laboratory under Biosafety Level 2 conditions.

170 Study outcomes

171 The primary simple endpoint was defined as death at 7 days after first dose of tocilizumab. 172 Secondary outcomes were admission to Intensive Care Unit (ICU), acute Respiratory 173 Distress Syndrome (ARDS) and respiratory insufficiency. We also assessed acute myocardial infarction, septic shock, acute kidney injury and secondary infections. Berlin 174 175 criteria for the ARDS were adapted, as many of the patients did not have an available 176 arterial O2 pressure due to the overwhelming volume of admitted patients that precluded us 177 from performing arterial blood samples on all patients. Instead, we used oxygen saturation 178 by pulse oximetry and its correlation to the inspired fraction of oxygen (SpO2/FiO2 ratio < 315).<sup>24,25</sup> One patient died a few hours after receiving tocilizumab and was excluded from 179 the primary endpoint analysis. 180

### 181 Statistical analysis

Continuous variables were expressed as mean and standard deviation or medians and 182 183 interguartile range, as appropriate. Categorical variables were summarized as absolute number and percentages. Comparisons among groups was performed with Chi squared test 184 185 and Fisher's test for categorical variables; and Student's T test and Mann-Whitney U test 186 for continuous variables. Box plots and bar plots are also provided for some associations. Mortality in the cohort was described with the use of Kaplan-Meier analysis. Tests were 187 considered significant when the two-tailed p-value was <0.05. We did not correct for 188 189 multiple comparisons; hence, the widths of the confidence intervals should not be interpreted as definitive for the associations with the outcomes. Association between time 190 191 to tocilizumab administration and mortality were assessed by means of Cox proportional 192 hazards regression. Missing urea and bilirubin levels on admission were assumed normal for CURB-65 and SOFA calculation; no other imputation was made for missing data. 193 194 Analysis was performed with Stata 15.1 software (StataCorp).

# 195196 Study oversight

- 197 The study was designed and conducted by the investigators from the Vall d'Hebron
- 198 COVID-19 Prospective Cohort Study. No specific funding was provided to conduct the
- 199 study. Data were collected, debugged, analysed and interpreted by the authors. All the
- authors reviewed the manuscript and vouch for the accuracy and completeness of the data
- and for the adherence of the study to the protocol.

202

## 203 **RESULTS:**

## 204 **Demographic and clinical characteristics**

- Since the onset of the COVID-19 outbreak until March 25<sup>th</sup>, 3242 respiratory-derived
- samples have been requested from our institution for COVID-19 diagnosis. Samples were
- 207 requested from the emergency room and hospital wards, as well as from the health care
- worker surveillance strategy plan. From them, 941 were positive (29%). During this period,
- 209 82 SARS-CoV-2 infected patients received at least one dose of tocilizumab. The mean
- 210 (±SD) age was 59.1 (±19.8) years (95% Confidence Interval 54.8-63.5). Fifty-two patients
- were male (63.5%). Eighteen (21.9%) patients were born abroad, 13 (16.1%) in Latin
- America, 3 (3.7%) in Eastern Europe and 2 (2.4%) in North Africa. The mean (±SD)
- duration of symptoms before hospital admission was  $6.7 (\pm 4.4)$  days. Fever and cough were
- the main symptoms on admission, occurring in 75 (91.5%) and 71 (86.6%) cases
- 215 respectively.
- 216 Thirty-three (40.3%) patients were former or active tobacco smokers. Coexisting conditions
- were as follows: 32 (39.0%) had hypertension, 19 (23.5%) had lung diseases (2 (2.4\%))
- asthma, 6 (7.3%) chronic obstructive pulmonary disease among others), 17 (20.7%) had
- obesity, 16 (19.5%) had diabetes mellitus, 11 (13.6%) had chronic kidney disease, 5 (6.1%)
- a history of cardiac failure, 1 (1.2%) had cirrhosis. Ten (12.5%) patients were
- immunosuppressed because of different conditions. Seventy-seven (95.1%) patients had a
- Barthel scale index of 100 points previous to hospital admission. Table 1 shows
- 223 demographic and clinical characteristics at baseline.
- 224 Laboratory and Radiologic findings

On admission, mean ( $\pm$ SD) white cell count was 9.2 (10.4) with 17 (21.3%) patients having

more than 10000 per cubic millilitre white cells. Lymphocytopenia (<1000 cells per cubic

227 millilitre) was present in 46 (57.5%) patients. Interleukin-6 median (IQR) plasma level on 228 admission was 74.8 (49.4-120.0) ng/ml. Liver enzymes were below five times the upper 229 normal value in all patients. Pneumonia was radiologically proven in all patients on 230 admission or during follow up. Tables 2 and 3 describe laboratory and radiologic findings 231 on admission and during follow up. 232 **Microbiologic results** 233 All included patients had a positive RT-PCR for SARS-CoV-2 in a respiratory-derived 234 sample. On admission, 2 patients out of 56 had a positive pneumococcal urinary antigen 235 result. Sputum samples from 13 patients were sent on admission, bacterial growth was 236 demonstrated in 3 samples, two with Haemophilus influenzae that were considered 237 clinically significant and one was deemed contamination with oral bacteria. During the first 7 days follow up, 2 more positive results were retrieved: one Extended-Spectrum Beta-238 239 Lactamase (ESBL)-producing Escherichia coli (considered clinically significant) and one Staphylococcus epidermidis (considered non-clinically significant). Blood cultures from 65 240 241 patients were sent, and one positive bacterial growth (coagulase-negative *Staphylococcus*) 242 was observed, although considered a contamination. Detailed microbiologic data are shown in Table 3. 243

# 244 Oxygen supplementation and secondary outcomes.

Table 4 shows oxygen saturation, oxygen supplementation and ventilation support. On

admission, mean FiO2 oxygen supplementation was  $0.36 (\pm 0.26)$  and mean oxygen

saturation was 94% (±4.39). Regarding oxygen supplementation devices on admission, 34

248 (41.5%) patients were on oxygen supplementation: two (5.8%) patients were on nasal

- cannulas, 22 (64.7%) were using face masks, 9 (26.5%) patients were using high oxygen
- supplementation devices and 1 (2.9%) patient required endotracheal intubation with

251	mechanical ventilation. Over time, SpO2/FiO2 ratio deteriorated from a median (IQR) of
252	428 (316.1-454.8) on admission, 271.4 (158.3-361.5) at 48 hours and 230.2 (118.8-346.4)
253	at 7 days follow up (p<0.001). Fifty-five (69.6%) patients required intensive oxygen
254	therapy, including high flow oxygen delivery systems, high flow nasal cannula, non-
255	invasive mechanical ventilation or invasive ventilation during the study period. Median
256	(IQR) days on high flow oxygen delivery systems, high flow nasal cannula, non-invasive
257	mechanical ventilation or invasive ventilation before progression to other intensive oxygen
258	therapy, outcome attainment or data censoring were 2.0 (1.0-3.0), 4.0 (2.0-6.0), 3.0 (2.0-
259	4.0) and 9.0 (9.0-9.0) respectively. The median (IQR) days from admission to first intensive
260	oxygen therapy was 2.0 (1.0-4.5). Only one (1.2%) patient required vasopressor therapy
261	due to hypotension. No patient required renal replacement therapy. Respiratory failure and
262	ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median (IQR) days
263	from symptoms to respiratory failure and ARDS were 8 (6.0-11.0) and 8 (5.0-11.0)
264	respectively. Median (IQR) days from admission to respiratory failure and ARDS were 1
265	(0.0-3.0) and 2 $(1.0-4.0)$ respectively. Secondary outcomes can be found in Table 5.
266	Tocilizumab treatment and concomitant treatment
267	Eighty-one (98.9%) patients received hydroxychloroquine, 63 (76.8%) lopinavir/ritonavir,
268	21 (25.61%) darunavir/cobicistat, and 79 (96.34%) azithromycin. All patients were initially
269	treated with antibiotic therapy, mainly ceftriaxone (77 (93.9%) patients). As expressed
270	before, all patients received at least one dose of tocilizumab. Median (IQR) time in days
271	from symptom onset to tocilizumab administration was 9.0 (6.0-11.0) and from admission

to tocilizumab administration was 2.0 (1.0-3.0)). Other treatments include cytokine

hemoadsorption therapy in 2 (2.4%) patients in ICU.

# 274 Primary outcome and mortality risk factors

275	Table 6 summarizes primary outcome in the study population. At the end of the follow up
276	period, of the 82 patients 34 (41.5%) had been discharged, 22 (26.8%) had died, 14 (17.1%)
277	were hospitalized in ICU, 9 (11.0%) were hospitalized in medical wards, and 3 (3.7%) had
278	been transferred to another institution. In the univariate analysis age, age-adjusted Charlson
279	comorbidity index, medical history of active or former solid cancer, hypertension, history
280	of heart failure, chronic kidney disease and worse age-adjusted Charlson index at baseline
281	were associated with increased risk of mortality (Table 7). By 7-day follow-up, the
282	mortality rate was 4.0% per person-day (95% confidence interval [CI], 2.4% to 6.2%) by
283	Kaplan-Meier analysis. Mortality was more frequent in patients receiving tocilizumab once
284	ARDS was present (hazard ratio for mortality 3.3; 95% CI, 1.3 to 8.5; age-adjusted hazard
285	ratio for mortality 2.1; 95% CI, 0.8 to 5.8)(Figure 1) or respiratory failure was present
286	(hazard ratio for mortality 3.13; 95% CI, 1.3 to 7.8; age-adjusted hazard ratio for mortality
287	2.4; 95% CI, 0.9 to 6.4)(Figure 2). When dividing patients according to the nearest
288	SpO2/FiO2 ratio to tocilizumab administration, mortality was higher among patients with
289	lower SpO2/FiO2 ratio (SpO2/FiO2 ratio<200, 46.2%; SpO2/FiO2 ratio 200-300, 16.7%;
290	SpO2/FiO2 ratio >300, 20.6%; p=0.03)(Figure 3). Distribution of the nearest SpO2/FiO2
291	ratio to tocilizumab administration depending on outcome groups was not statistically
292	significant (mean (SD) SpO2/FiO2 ratio: 321.3 (154.7) dead, 343.1 (132.7) ICU, 396.9
293	(96.2) alive; p=0.2)(Figure 4). No correlation was observed between nearest IL-6 levels to
294	tocilizumab administration and main outcome (median (IQR) IL-6 levels: 79.7 (48.2-128.1)
295	dead, 77.5 (55-120) ICU admission, 71.4 (49.4-116) alive; p=0.92). Basal characteristics of
296	patients stratified by ARDS and respiratory failure can be found in the Supplementary
297	Appendix.

298 Safety

299 300	Twelve (14.63%) out of 82 patients reported a total of 14 adverse events during the follow
301	up. Thirteen (92.9%) adverse events were considered related to lopinavir/ritonavir, 9
302	(75.0%) patients discontinued lopinavir/ritonavir treatment due to gastrointestinal
303	symptoms. Diarrhoea was the most common reported adverse event. Other adverse events
304	included nausea and dysuria. There were no adverse events attributed to tocilizumab. No
305	serious adverse events were reported during follow up, and only 2 (14.3%) were considered
306	moderate. Eleven (91.7%) patients recovered without medical sequelae and one patient had
307	an unknown outcome. No tocilizumab discontinuation was reported due to adverse events.
308	

# 309 **DISCUSSION**

310	This preliminary report from the Vall d'Hebron COVID-19 Prospective Cohort Study
311	describes the characteristics and clinical outcomes of patients who were hospitalized in
312	non-ICU wards and received treatment with tocilizumab. Our results show that a timely
313	administration of immune-modulating therapies, before the onset of respiratory
314	insufficiency or ARDS, may improve severe COVID-19 patients' outcomes.
315	Therapies to improve outcomes of patients with COVID-19 focus on viral-directed
316	therapies and host-directed therapies. There is still lack of evidence about the efficacy of
317	any of these therapies, although this does not prevent physicians to use all sorts of off-label
318	therapies despite the risk of serious adverse events. <sup>26</sup> Therapies to curb uncontrolled
319	cytokine release have been proposed and are being widely used. Randomized controlled
320	trials with host-directed therapies are currently under way and results will be available
321	within the next months. <sup>17,18</sup> Meanwhile, data from prospective studies can help to improve
322	COVID-19 patient management. In our study, the 7-day mortality was 26.8%, slightly
323	higher than a recent experience with remdesivir and similar to the mortality of 22.1%
324	reported in another study with lopinavir/ritonavir. <sup>27,28</sup> However, the patients in our
325	prospective cohort had more coexisting conditions, including potential mortality risk
326	factors such as hypertension, other cardiovascular and metabolic diseases, chronic kidney
327	disease and cancer.
328	The understanding of mortality risk factors in patients with COVID-19 is an evolving
329	matter. Age, specific coexisting conditions and laboratory parameters may help identify
330	patients with poor outcome. <sup>29</sup> As expressed before, in our cohort of patients treated with
331	tocilizumab, hypertension, history of cardiac failure and chronic kidney disease were
332	associated with higher mortality in the univariate analysis. Antihypertensive agents, such as

333	angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers
334	(ARB), have been suggested to be associated with the increased mortality observed in this
335	subset of patients. Angiotensin converting enzyme 2 plays an important role in SARS-CoV-
336	2 viral entry as co-receptor. <sup>30</sup> Hypothesis outline that the interactions between these drugs
337	and co-receptors may increase viral spreading in the lung and increase risk of death.
338	However, the evidence is limited and no specific recommendations could be drawn from
339	current evidence, especially when ACEI and ARB have shown to reduce mortality in this at
340	risk population. <sup>31</sup> The Vall d'Hebron COVID-19 Prospective Cohort Study has among its
341	main objectives to analyse the role of these and other drugs used to treat chronic conditions
342	in the prognosis of patients with COVID-19.
343	Host-directed therapies aiming at blocking an unrestrained immune response and an
344	excessive inflammation have been proposed as potential therapies to prevent acute lung
345	injury and subsequent ARDS. SARS-CoV-2 infection severity has been associated with an
346	increase in IL-6 and D dimer levels, and the cytokine profile resembles that of other
347	conditions in which host-directed therapies have been successfully used. <sup>13,29,32</sup> Timely use
348	of host-directed therapies may curb uncontrolled cytokine release and prevent damage
349	inflicted by hyperinflammation. Tocilizumab has shown to be safe in two small Chinese
350	cohort studies of patients with COVID-19.9,16 Efficacy of tocilizumab, measured as hospital
351	discharge, was 90.5% (19 out of 21 patients) in patients with COVID-19 needing oxygen
352	supplementation and having elevated IL-6 in one study <sup>9</sup> ; while the other study showed 3
353	deaths, 10 clinical stabilizations and 2 clinical aggravations out of 15 patients. <sup>16</sup> Other
354	laboratory and radiologic findings also improved in a short period of time. However,
355	standard of care in the studies was different limiting the possibility of direct comparisons.
356	As in other infections and inflammation-driven diseases, timely initiation of precise therapy

357 is the mainstay of patient management and directly affects mortality and morbidity. Our 358 study showed that patients receiving prompt treatment with tocilizumab before lung injury is established have less 7-day mortality, a benefit that may be sustained in the long-term.<sup>33</sup> 359 360 The safety profile of tocilizumab has been extensively studied in clinical trials with patients 361 suffering autoimmune diseases. The most common adverse events of intravenous 362 tocilizumab in a pooled analysis of 3 clinical trials were upper respiratory infections, 363 nasopharyngitis, headache, hypertension and increase in liver enzymes. Serious adverse events occurred in 12% of the patients, infectious diseases being the most common.<sup>34</sup> In our 364 365 study we did not report any serious adverse events, although the symptoms of systemic viral infections may mimic any adverse event and make its identification difficult. 366 367 Tozilizumab-related bacterial infections were not reported in our study. Two factors may have contributed to this: first, many patients were under antibiotic treatment, and second, 368 369 the short follow up period precludes us from any further analysis. Nevertheless, the low 370 cumulative dose administered in this subset of patients may diminish the likelihood of 371 infectious adverse events. 372 In a time of scarce medical resources, including limited stock of host-directed therapies, hard medical decisions have to be done by front-line physicians. Allocation of therapies to 373 patients with the highest chances of a favourable outcome should be encouraged, 374 maximizing the benefit of the intervention.<sup>35</sup> Evidence-based decision-making and benefit-375 376 maximizing allocation of the available resources should be promoted. In this regard our 377 study can help physicians to better allocate host-directed therapy in patients with COVID-19 prioritizing moderate-to-severe ill patients over critically ill patients. 378 This preliminary exploratory study has several limitations. First, there is no control group 379 380 and the minimum follow up period was 7 days. Therefore, at this point it is not possible to

381	evaluate the differences between patients receiving tocilizumab or not and, consequently, it
382	is not possible to evaluate solidly what is the overall benefit of administering this drug.
383	However, the urgency of obtaining data on new therapies justifies the early communication
384	of these results. Second, ICU admission is not a very robust endpoint since it depends on
385	the attitudes of the treating physicians as well as the availability of beds at times of resource
386	scarcity and overwhelming demand. For this reason, mortality was selected as the main
387	outcome in our study. Besides, the subsequent analysis of all patients included in the Vall
388	d'Hebron COVID-19 Prospective Cohort Study may solve this limitation and inform results
389	with a longer follow up period. Finally, our data is limited to a single centre. While our
390	results may not be extrapolated to other populations or other standards of care, the
391	management of patients was homogeneous avoiding the centre effect of multicentric
392	studies. Multivariate analysis is limited by sample size.

# 393 CONCLUSION

394	In summary, we found a mortality rate of 26.8% in this subset of patients with COVID-19
395	receiving tocilizumab for the treatment of inflammatory-related lung injury. Time from
396	lung injury onset to tocilizumab administration may be critical to patient recovery. Our
397	results may help front-line physician to make evidence-based decisions in times of scarce
398	resources and operationalized fair and transparent allocation procedures, maximizing the
399	benefit of the intervention. Future and current host-directed clinical trials for patients with
400	COVID-19 should consider our preliminary data in their design. All our patients were
401	treated with a combination of antiviral drugs whose efficacy is yet to be demonstrated.
402	Host-directed therapies in the absence of antiviral drugs needs further investigation.

# 403 ACKNOWLEGDEMENT

- 404 None
- 405 **CONFLICTS OF INTEREST**
- 406 None
- 407

## 408 **CONTRIBUTION STATEMENT:**

409 Conceived the idea: ASM, JEP, JSN, NFH, BA • Reviewed medical chart and collected data. ASM, JSM, JEP, NFH, FS, XD, MM, AA, 410 • SEE, ASG, AMP, PBM, SA, JS, AGdC. 411 Supervised the findings: ASM, JEP, JSN, NFH, BA 412 ٠ Performed statistical analysis: ASM, JEP, NFH, SPH 413 • 414 Wrote the manuscript with inputs from all authors: ASM, JEP, NFH • 415 Supervised the project: ASM, JS, BA ٠ 416 Interpretation of the results: ASM, JSM, JEP, NFH, FS, XD, MM, AA, SEE, ASG, AMP, ٠ 417 PBM, SA, JS, AGdC. Critically reviewed the manuscript: ASM, JSM, JEP, NFH, FS, XD, MM, AA, SEE, ASG, 418 • 419 AMP, PBM, SA, JS, AGdC.

420

## 421 **REFERENCES**

422 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel 423 coronavirus in Wuhan, China. Lancet Lond Engl 2020;395(10223):497-506. 424 2. Novel Coronavirus (2019-nCoV) situation reports [Internet]. [cited 2020 Apr 1];Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-425 2019/situation-reports 426 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The 427 3. 428 epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua 429 Liuxingbingxue Zazhi 2020;41(2):145-51. 430 Hauser A, Counotte MJ, Margossian CC, et al. Estimation of SARS-CoV-2 mortality 431 4. 432 during the early stages of an epidemic: a modelling study in Hubei, China and northern Italy. medRxiv 2020;2020.03.04.20031104. 433 De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus 434 5. 435 infections. Expert Rev Anti Infect Ther 2006;4(2):291-302. 436 6. Al-Tawfig JA, Memish ZA. Update on the apeutic options for Middle East 437 Respiratory Syndrome Coronavirus (MERS-CoV). Expert Rev Anti Infect Ther 2017;15(3):269-75. 438 7. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a 439 440 treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J 441 Antimicrob Agents 2020;105949. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with 442 8. COVID-19: results of a randomized clinical trial. medRxiv 443 2020:2020.03.22.20040758. 444 Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with 445 9. 446 tocilizumab. Available from: chinaXiv:202003.00026v1 (2020). www.chinaxiv.org/abs/202003.00026 447 448 10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated 449 with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost JTH 2020; 450 451 11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-452 nCoV acute respiratory disease. Lancet Lond Engl 2020;395(10223):e30-1. 453 12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 454 2020;395(10229):1033-4. 455

456 457 458	13.	Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019- nCoV: host-directed therapies should be an option. Lancet Lond Engl 2020;395(10224):e35–6.
459 460 461	14.	Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2019;13:57–70.
462 463	15.	Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127(26):3321–30.
464 465	16.	Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;
466 467 468	17.	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Apr 11];Available from: https://clinicaltrials.gov/ct2/show/NCT04315298
469 470 471	18.	Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Apr 11];Available from: https://clinicaltrials.gov/ct2/show/NCT04331665
472 473 474	19.	Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377–82.
475 476	20.	Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis. JAMA 2016;315(8):762–74.
477 478	21.	World Health Organization. Laboratory testing for 2019 novel coronavirus (2019- nCoV) in suspected human cases. WHO - Interim Guid 2020;2019(January):1–7.
479 480 481	22.	Moës E, Vijgen L, Keyaerts E, et al. A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis 2005;5:6.
482 483 484	23.	Woo PCY, Lau SKP, Lam CSF, et al. Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in Gammacoronavirus. J Virol 2014;88(2):1318–31.
485 486	24.	Force TADT. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012;307(23):2526–33.
487 488 489	25.	Festic E, Bansal V, Kor DJ, Gajic O. SpO2/FiO2 Ratio on Hospital Admission Is an Indicator of Early Acute Respiratory Distress Syndrome Development Among Patients at Risk. J Intensive Care Med 2013;30(4):209–16.

490 491	26.	Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA 2020;
492 493	27.	Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;
494 495	28.	Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;
496 497 498	29.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl 2020;395(10229):1054–62.
499 500	30.	Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270–3.
501 502	31.	Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020;
503 504	32.	Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124(2):188–95.
505 506 507	33.	Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirol Carlton Vic 2010;15(3):543–50.
508 509 510 511	34.	Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580–4.
512 513	35.	Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med 2020;

514

# 515 **FIGURES**

- 516 Figure 1. 7-day mortality curves according to the moment patients received tocilizumab:
- 517 before or after developing ARDS. ARDS: acute respiratory distress syndrome.
- 518 Figure 2. 7-day mortality curves according to the moment patients received tocilizumab:
- 519 before or after developing respiratory insufficiency.
- 520 Figure 3. Outcome according to nearest SpO2/FiO2 ratio to tocilizumab administration
- 521 Figure 4. Nearest SpO2/FiO2 ratio to tocilizumab administration distribution according to
- 522 7-days outcome
- 523

# 524 TABLES

525 **Table 1.** Demographic and clinical characteristics of the patients at baseline\*

Characteristics	Patients (n=82)
Age, mean - yr	59.1 ±19.8
Sex – no (%)	
Male	52 (63.4%)
Female	30 (36.6%)
Origin	
Spain	63 (77.8%)
Latin America	13 (16.1%)
East Europe	3 (3.7%)
North Africa (Magreb)	2 (2.4%)
Coexisting condition – no (%)	
Active tabacco smoker	5 (6.1%)
Former tabacco smoker	28 (34.2%)
Never smoke	49 (59.8%)
Active daily alcohol consumption	1 (1.2%)
Former daily alcohol consumption	2 (2.4%)
Never drink daily	79 (96.3%)
Cognitive imparment	1 (1.2%)
Diabetes Mellitus	16 (19.5%)
Immunosuppression	10 (12.2%)
Solid organ transplant	5 (6.1%)
Drug induced immunosuppression	3 (3.7%)
Bone marrow transplant	1 (1.2%)
Other	1 (1.2%)
Former cancer (includes any solid cancer)	9 (11.1%)
Active cancer (includes any solid cancer)	2 (2.4%)
Former haematological condition (includes	3 (3.7%)
leukemia and lymphoma)	
Active haematological condition (includes	2 (2.4%)
leukemia and lymphoma)	
Hypertension	32 (39%)
Hystory of cardiac failure	5 (6.1%)
Atrial fibrillation	10 (12.2%)
Lung diseases ¬	19 (23.5%)
Chronic obstructive pulmonary disease	6 (7.3%)
Obstructive sleep apnea syndrome	3 (3.7%)
Insterstitial lung disease	2 (2.4%)
Asthma	2 (2.4%)
Bronchiectasis	2 (2.4%)
Lung restritive disease	2 (2.4%)
Lung transplant	2 (2.4%)
Pulmonary hypertension	1 (2.4%)

Controlled pulmonary tuberculosis	1 (2.4%)
Chronic kidney disease	11 (13.6%)
GFR>50	3 (27.3%)
GFR 30-50	4 (36.4%)
GFR<30	4 (36.4%)
Renal supportive therapy (hemodyalisis)	2 (18.2%)
Cirrhosis	1 (1.2%)
Central nervous system disease	2 (2.4%)
Obesity	17 (20.7%)
Mean duration of symptom before admission	6.7 ±4.4
(days)	
Mean days from symptom onset to dyspnea	1.14 ±3.6
Mean duration of dyspnea before admission	3.48±3.2
Symptoms	
Fever	75 (91.5%)
Cough	71 (86.6%)
Shortness of breath	54 (65.9%)
Sore throat	1 (1.2%)
Sputum production	8 (9.8%)
Rhinorrhea	1 (1.2%)
Headache	1 (1.2%)
Lost of weigth	4 (4.9%)
Malaise	46 (56.1%)
Hemoptysis	5 (6.1%)
Chest pain	21 (25.6%)
Anosmia	4 (4.9%)
Cacosmia	3 (3.7%)
Muscle and joint pain	14 (17.1%)
Nauseas	3 (3.7%)
Vomits	36 (43.9%)
Diarrhea	8 (9.8%)
Profuse sweating	2 (2.4%)
Barthel scale 100 previous to symptoms	77 (93.9%)
onset†	
ECOG ≤ 1 previous to symtoms onset ‡	78 (95.1%)
Median (IQR), age-adjusted Charlson index at	3 (1-4)
baseline - points ∫	
Median (IQR), SOFA index at admission –	1 (0-3)
points ¶	
CURB-65 ≥ 3 §	18 (22%)

<sup>526</sup> \*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be

527 100 because of rounding.

528 +Barthel index total scores range from 0 to 100, with higher scores indicating a better

529 performance of 10 basic daily self-care activities. ‡ The Eastern Cooperative Oncolgy Group (ECOG)

performance scale range from 0 (fully active) to 4 (completely disabled). J The Charlson risk index

- score ranges from 0 to 37 with higher scores indicating a higher risk of death. ¶ Sequential Organ
- 532 Failure Assessment (SOFA) score ranges from 0 to 24 with higher ranges indicating a higher risk or
- 533 morbidity; individuals with a score of 15 or more have a mortality rate of 90%. Its calculation is
- 534 missing in two patients. § Community acquired pneumonia severity index assessing Confusion,
- 535 Urea, Respiratory rate, Blood pressure and age over 65 years (CURB-65) ranges from 0 to 5
- 536 depending on the number of risk factors present in the same patient.
- 537 GFR: glomerular filtration rate.
- 538 One patient had insterstitial lung disease and pulmonary hypertension and another patient had
- 539 obtructive sleep apnea syndrome and lung restrictive disease.

# Table 2. Status on admission and follow up\*

	Admission (n=82) +	48 hours (n=79) †	7 days (n=51) †
Vital signs on admission – no. (%)			
Systolic blood pressure, mean - mmHg	128.3±18.3	120.8 ±17.7	125.0 ±19.4
Diastolic blood pressure, mean - mmHg	73 ±12.2	71.3 ±9.3	72.3 ±10.7
Temperature, mean - ºC	37.7 ±0.9	36.8 ±0.8	36.4 ±0.7
Heart rate, mean - rates per minute	94.3 ±17.8	79.7 ±12.0	79.0 ±14.2
Respiratory rate, mean - breaths per minute	23.9 ±6.3	21.5 ±6.0	22.5 ±11.5
Temperature > 37.8ºC	34 (42.5%)	9 (12.1%)	1 (1.6%)
Heart rate > 100 beats per minute	28 (65.4%)	3 (3.8%)	7 (11.5%)
Respiratory rate > 20 breaths per minute	39 (58.2%)	24 (40%)	23 (46.9%)
Oxygen saturation, mean	94.0 ±4.4	94.1 ±3.9	93.6 ±6.9
Physical examination – no. (%)			
Glasgow coma scale of 15	82 (100%)		
Abnormal lung sounds			
Crackles	62 (75.6%)	54 (67.5%)	39 (58.2%)
Hypophonesis	9 (11%)	7 (8.6%)	5 (7.5%)
Wheezing	5 (6.1%)	2 (2.5%)	0 (0%)
Rhonchus	5 (6.1%)	2 (2.5%)	2 (3%)
Imaging characteristics – no. (%)			
Type of chest radiography alteration <sup>+</sup>			
Unilateral or bilateral infiltrate	20 (24.4%)	17 (21.3%)	21 (31.3%)
Interstitial pattern	10 (12.2%)	4 (5%)	7 (10.5%)
Pleural effusion	2 (2.4%)	1 (1.3%)	0 (0%)
Atelectasis	1 (1.2%)	1 (1.3%)	0 (0%)
Extension of abnormality in chest radiography			
PA projection			
<33%	32 (39.0%)	4 (5%)	4 (5.97%)
33-66%	38 (46.3%)	6 (7.5%)	9 (13.43%)
>66%	10 (12.2%)	9 (11.25%)	13 (19.45%)

\*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

+Total number of patients varies among variables and follow up as mortality increases.

\$Some patients have more than one radiologic abnormality.

PA, posteroanterior.

Table 3. Laboratory data at admission and follow up\*

Laboratory data – no. (%)	Admission (n=82) +	48 hours (n=79) †	7 days (n=51) †
Red cell count			
Haemoglobin, mean – gr/dl	13.3 ±1.6	12.7 ±1.6	12.5 ±1.5
≥ 10 gr/dl – no. (%)	78 (96.3%)	41 (93.2%)	43 (95.6%)
White cell count			
Mean (SD) – per mm <sup>3</sup>	9.2 ±10.4	6.7 ±3.8	7.1 ±3.5
Distribution – no. (%)			
≥ 10000/mm <sup>3</sup>	17 (21.3%)	5 (11.4%)	9 (20%)
≤4000/mm³	7 (8.8%)	10 (22.7%)	9 (20%)
Lymphocyte count			
Meidan (IQR) – per mm <sup>3</sup>	868.9 (593.7-1205.5)	710.5 (491.5-1154.9)	1112.0 (575.1-1519.6)
Distribution – no. (%)			
≥ 1000/mm³ – no. (%)	34 (42.5%)	15 (34.1%)	23 (51.1%)
Platelet count, mean – per mm <sup>3</sup>	199 ±87.2	235.7 ±139.4	282.3 ±141.6
Prothrombin time, mean - %	77.9 ±23.8		
Activated partial thrombopastin time, mean -	24.6 ±9.8		
seconds			
Fibrinogen, mean – gr/dl	5.6 ±1.0		
D dimer, median (IQR) - ng/ml	295 (201-437)	565 (303-772)	738 (273.5-2963)
Glucose, mean - mg/dl	120.2 ±36.7		
Urea, median (IQR) – mg/dl	43 (38-72)		
Serum creatinine, mean - mg/dl	1.7 ±6.1	2.1 ±7.1	0.9 ±0.6
Glomerular filtrate, mean – CKD-EPI	73.5 ±23.8	73.1 ±26.5	77.25 ±19.9
Sodium, mean – mmol/L	136.0 ±3.7		
Potasium, mean – mmol/L	3.9 ±0.7		
Calcium, mean – mg/dl	8.9 ±0.5		
Total bilirubin, mean – mg/dl	0.7 ±0.5		
Aspartate aminotransferase, mean - U/litre	53.1 ±34.3	53.7 ±35.4	71.4 ±46.2
Aspartate aminotransferase > 40 U/litre	42 (53.9%)	25 (61%)	30 (66.7%)

Alanine aminotransferase, mean - U/litre	41.68 (34.4)	43.4 (31.7)	77.3 (71)
Alanine aminotransferase > 40 U/litre	28 (35.4%)	16 (39.0%)	30 (66.7%)
Alkaline phosphatase, mean - U/litre	69.80 ±21.7		
Gamma-glutamyl transferase, mean – U/litre	93 ±58.0		
LDH, mean - UI/L	446.61 ±79.5		
CRP, mean - mg/dl	17.98 ±11.7	17.5 ±10.0	6.3 ±9.2
Ferritin, mean - ng/ml	885.69 ±500.5	1505.4 ±1194.6	1241.6 ±789.2
Proteins, mean - gr/dl	7.38 ±0.7		
Albumin, mean - gr/dl	3.30 ±0.3		
IL-6, median (IQR) - pg/ml	74.8 (49.4-120.0)	184.1 (75.3-592.6)	501.2 (103.7-2361.0)
Infection analysis			
Positive blood cultures	1 (1.3%)	0 (0%)	1 (10%)
Positive sputum cultures	3 (4.3%)	0 (0%)	2 (22.2%)
Positive pneumococcal urinary antigen	2 (2.5%)	0 (0%)	0 (0%)

\*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

<sup>+</sup>Total number of patients varies among variables and follow up as mortality increases.

	Admission (n=82) +	48 hours (n=79) †	7 days (n=51) †
Respiratory frequency, mean – rate per	23.9 ±6.3	21.6 ±6	22.5 ±11.5
minute			
Oxygen saturation, mean	94 ±4.4	94 ±3.9	93.6 ±6.9
SpO2/FiO2 ratio, median (IQR)	428 (316.1-454.8)	271.4 (158.3-361.5)	230.2 (118.8-346.4)
Oxygen supplementation and supportive			
ventilation – no. (%)			
Nasal cannula	2 (5.9%)	6 (9%)	4 (7.0%)
Face masks	22 (64.7%)	33 (49.3%)	16 (28.1%)
High oxygen supplementation device	9 (26.5%)	11 (16.4%)	6 (10.5%)
High flow nasal cannulas	0 (0%)	10 (14.9%)	16 (28.1%)
Non-invasive mechanical ventilation	0 (0%)	2 (3%)	3 (5.3%)
Invasive mechanical ventilation	1 (2.9%)	5 (7.5%)	12 (21.1%)

Table 4. Oxygen supplementation and supportive ventilation on admission and follow up\*

\*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

+Total number of patients varies among variables and follow up as mortality increases.

SpO2/FiO2 ratio: arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen

**Table 5.** Secondary outcomes at 7-day follow up from tocilizumab administration.

Outcome – no. (%)	Patients
Vasopressor therapy	15 (19.7%)
Acute respiratory distress syndrome	45 (64.3%)
Respiratory failure	62 (84.9%)
Cardiac failure	1 (1.5%)
Septic shock	1 (1.6%)
Acute kidney injury	9 (13.9%)
Concomitant infection	1 (1.5%)

**Table 6.** Main outcome at 7-day follow up from tocilizumab administration.

Main outcomes – no. %	Patients
Discharge	34 (41.5%)
In-patient in conventional ward	9 (11.0%)
Intensive care unit	14 (17.1%)
Death	22 (26.8%)
Transferred	3 (3.7%)

# Table 7. Comparison of risk factors by in-hospital mortality.

Characteristics	Alive (n=60)	Dead (n=22)	P-value
Demographics			
Age, mean (SD) - yr	53.3 (19.9)	75.2 (6.2)	<0.001
Sex – no (%)	36 (60.0)	16 (72.7)	0.289
Coexisting condition – no (%)			
Tobacco use			0.397
Active tabacco smoker	5 (8.3)	-	
Former tabacco smoker	19 (31.7)	9 (40.9)	
Never smoke	36 (60.0)	13 (59.1)	
Alcohol use			0.070
Active daily alcohol consumption	1 (1.7)	-	
Former daily alcohol consumption	-	2 (9.1)	
Never drink daily	59 (98.3)	20 (90.9)	
Barthel index at admission, median (IQR)	100 (100-100)	100 (100-100)	0.371
Dementia	1 (1.7)	-	1
Diabetes Mellitus	12 (20.0)	4 (18.2)	1
Immunosuppression	5 (8.3)	5 (22.7)	0.123
Solid tumor	3 (5.1)	6 (27.3)	0.012
Leukemia/Lymphoma	2 (3.3)	1 (4.6)	1
Hypertension	17 (28.3)	15 (68.2)	0.001
Chronic heart failure	1 (1.7)	4 (18.2)	0.017
Chronic lung disease	11 (18.6)	8 (36.4)	0.094
Chronic renal failure	4 (6.7)	7 (33.3)	0.005
Liver cirrhosis	1 (1.7)	-	1
Central nervous system disease	1 (1.7)	1 (4.6)	0.467
Obesity	14 (23.3)	3 (13.6)	0.539
Median (IQR), age-adjusted Charlson index at baseline - points	2 (1 - 3)	5 (3 – 6)	<0.001
Oxygenation previous to tocilizumab administration			

Oxygen saturation (pulse oximeter) at baseline, median (IQR)	95 (94 - 97.5)	93 (89 - 97)	0.061
FiO2 at baseline, median (IQR)	0.21 (0.21 - 0.28)	0.26 (0.21 - 0.50)	0.130
SpO2/FiO2 ratio at baseline, median (IQR)	440 (343-455)	393 (180-452)	0.134
High oxygen supplementation or ventilation at baseline* - no. (%)	-	1 (4.6%)	0.268
Oxigen saturation (pulse oximeter) at tocilizumab administration, median (IQR)	95 (93-97)	92 (89-94)	0.006
FiO2 previous to tocilizumab administration, median (IQR)	0.27 (0.21-0.40)	0.35 (0.21-1)	0.131
SpO2/FiO2 ratio previous to tocilizumab administration, median (IQR)	354 (228-438)	263 (95-423.8)	0.072
High oxygen supplementation or ventilation previous to tocilizumab administration*	3 (5%)	4 (18%)	0.79
Days from initial symptoms to tocilizumab administration, median (IQR)	9 (7 - 11)	7 (5 - 15)	0.372
Days from admission to tocilizumab administration, median (IQR)	2 (1 - 3)	3 (1 - 4)	0.064
Days from respiratory insufficiency to tocilizumab administration, median (IQR)	0 (0 - 1)	1 (0 - 2)	0.055
Days from ARDS to tocilizumab administration, median (IQR)	0 (-1 - 0)	0 (0 - 1)	0.132

\*Plus-minus values are means ( $\pm$ SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

<sup>†</sup>Includes high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation

ARDS: acute respiratory distress syndrome.